Table 3. Univariate analysis of overall survival.
| Variable | Hazard ratio | 95% C.I. | P |
|---|---|---|---|
| Age, years (continuous) | 1.03 | 1.01–1.05 | 0.01 |
| Stage I/II vs. III/IV | 2.72 | 0.85–8.72 | 0.09 |
| Grade 1/2 vs. 3 | 1.26 | 0.50–3.14 | 0.63 |
| Histology, serous vs. others | 0.66 | 0.32–1.34 | 0.25 |
| Residual tumor, absent vs. present | 1.20 | 0.71–2.05 | 0.50 |
| Stromal TILs (lowest tertile vs. all others) | |||
| CD3+ | 0.70 | 0.40–1.20 | 0.19 |
| CD4+ | 0.89 | 0.51–1.56 | 0.68 |
| CD8+ | 0.71 | 0.41–1.22 | 0.22 |
| CD8+/CD4+ ratio | 1.23 | 0.70–2.16 | 0.48 |
| CD20+ | 0.77 | 0.45–1.32 | 0.34 |
| Intraepithelial TILs (lowest tertile vs. all others) | |||
| CD3+ | 0.92 | 0.54–1.55 | 0.74 |
| CD3+ (according to Zhang et al. in ref. 6) | 0.89 | 0.53–1.49 | 0.64 |
| CD4+ | 0.84 | 0.50–1.40 | 0.50 |
| CD8+ | 0.51 | 0.30–0.85 | 0.01 |
| CD8+/CD4+ ratio | 0.42 | 0.25–0.72 | 0.002 |
| Treg | 1.28 | 0.74–2.24 | 0.38 |
| CD25+FOXP3– | 0.61 | 0.35–1.04 | 0.07 |
| CD8+/Treg ratio | 0.33 | 0.18–0.59 | 0.0002 |
| CD8+/CD25+FOXP3– ratio | 0.98 | 0.56–1.71 | 0.94 |
Univariate Cox proportional hazards model. Whereas high intraepithelial CD8+ TILs, CD8+/CD4+ ratio, and CD8+/Treg ratio were associated with improved survival, stromal TIL subtypes and other intraepithelial TILs were not significant. Age, stage, grade, histological type, and presence of residual disease were adopted as covariates. Classification of CD3+ TILs by Zhang et al. (6) was applied but was not associated with improved survival.